A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

Although a cure for HCV is on the near horizon, emerging drug cocktails will be expensive, associated with side-effects and resistance making a global vaccine an urgent priority given the estimated high incidence of infection around the world. Due to the highly heterogeneous nature of HCV, an effect...

Full description

Bibliographic Details
Main Authors: John Lok Man Law, Chao Chen, Jason Wong, Darren Hockman, Deanna M Santer, Sharon E Frey, Robert B Belshe, Takaji Wakita, Jens Bukh, Christopher T Jones, Charles M Rice, Sergio Abrignani, D Lorne Tyrrell, Michael Houghton
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3602185?pdf=render

Internet

http://europepmc.org/articles/PMC3602185?pdf=render

Similar Items